News - Polyphor - The Latest IPO on SIX Swiss Exchange
Today marked the first trading day of Polyphor
(listing video) shares on
SIX Swiss Exchange, with an opening price of CHF 40.00. Polyphor shares are listed in accordance with the
International Reporting Standard
and included in the
SXI Life Sciences® and
SXI Bio+Medtech® indices.
"With Polyphor, we are delighted to welcome another company from the life science sector to SIX Swiss Exchange. With around
40% of the European free float market capitalization, we are Europe's leading stock exchange for the life
science sector," said Werner Bürki, Head Trading, SIX, Securities & Exchanges. "The latest IPO joins a number
of other successful life sciences companies on the Swiss stock exchange and underlines our leading position."
Since June 2017, the three life science companies - Idorsia, Medartis and Polyphor - have opted to go public on SIX Swiss Exchange.
Giacomo Di Nepi, Chief Executive Officer of Polyphor, said: "I am delighted that our Initial Public Offering was so successful.
The listing on the SIX Swiss Exchange allows us to raise CHF 155 million to bring our products to patients affected by infections and
hospital pneumonia and to women with metastatic breast cancer as well as to fund our future. Our IPO is the largest biotech IPO in
Switzerland in over 10 years and one of the top three in Europe in the last three years in terms of proceeds raised by an issuer to
finance the development of its pipeline. I would like to thank all investors who placed their trust in our science, team and programs
and all the colleagues and professionals who supported us throughout the process."
From left: Daniel Obrecht, Chief Scientific Officer, Kalina Scott, Chief Financial Officer, Giacomo Di Nepi, Chief Executive
Officer, Debra Braker, Chief Medical & Development Officer
Future development thanks to IPO
Polyphor is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland. Its leading drug candidate, an antibiotic
called Murepavadin, recently entered into Phase III clinical trials. Giacomo Di Nepi, Polyphor CEO: "The IPO will allow
us to continue the development of Murepavadin to treat hospital-acquired pneumonia, which has mortality rates of approximately
30% - 40%, and drive forward the development of Balixafortide
and other innovative antibiotics."
Numerous benefits for equity issuers
A listing on SIX Swiss Exchange provides companies with access to strongly capitalized Swiss and international investors.
In addition, we make things as simple as possible for them with first-class, needs-oriented services, allowing issuers
to efficiently raise capital and achieve sustainable growth. Our appeal extends far beyond the borders of Switzerland.
An overview and helpful information on all topics relevant to going public on SIX Swiss Exchange can be found
in our comprehensive Going Public Guide
or in the compact "IPO Guide Schweiz" (available in German only). Further information on our range of
services for issuers can be found on our website.
Show all news